



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/726,643	12/01/2000	Steven M. Ruben	PZ040P1	2092

22195 7590 05/31/2002

HUMAN GENOME SCIENCES INC  
9410 KEY WEST AVENUE  
ROCKVILLE, MD 20850

EXAMINER
----------

SPIEGLER, ALEXANDER H

ART UNIT	PAPER NUMBER
----------	--------------

1637

DATE MAILED: 05/31/2002

9

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.

09/726,643

Applicant(s)

RUBEN ET AL.

Examiner

ALEXANDER SPIEGLER

Art Unit

1637

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 12 March 2002.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 11, 12, 14 and 24-75 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 11, 12, 14, 24-75 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

  
SHARON N. THORNTON  
PATENT ANALYST

## Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

## Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_
- 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_\_

**DETAILED ACTION*****Election/Restrictions***

1. Applicant's election with traverse of Group II (claims 11-12 and 14) in Paper No. 8 is acknowledged. The traversal is on the ground(s) that the examiner has not shown that the search and examination of the groups would entail a "serious burden" to the examiner. This is not found persuasive because it is maintained that undue burden would be required to examine the claims of groups I and III-IX along with the claims of group II as evidenced by the fact that the claims of groups I-IX have acquired a separate status in the art as recognized by their different classification and as recognized by their divergent subject matter and because a search of the subject matter of invention II is not co-extensive with a search of inventions I and III-IX.

The requirement is still deemed proper and is therefore made FINAL.

2. Originally filed claim 17 has been cancelled by the Applicants in the Amendment received March 12<sup>th</sup>, 2002. Newly filed claims 24-75 are drawn to the elected invention, however, newly submitted claim 76 is drawn to a non-elected invention (i.e. a method for preventing, treating or ameliorating a medical condition by administering the polypeptide of SEQ ID NO: 56). Therefore, claims 1-10, 13, 15-16, 18-23 and 76 are withdrawn from consideration.

***Claim Rejections - 35 USC § 112***

3. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

4. Claims 11-12, 14, 30-35, 41-45, 51-55, 61-65 and 71-75 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

A) Claims 11, 12 and 14 are indefinite because it is not clear as to what is being claimed. Furthermore, it is not clear as to what is meant by "secreted form", "variant", "allelic variant" or "species homologue" means. These terms are not defined in the specification. In addition, Applicants should amend the claim to recite specific SEQ ID NO:

B) Claims 30-35, 41-45 and 61-65 over "the secreted portion" because this recitation lacks antecedent basis.

C) Claims 31-32, 51-55 and 71-72 over "the complete polypeptide" because this recitation lacks antecedent basis.

D) Claims 30-35, 41-45, 51-55, 61-65 and 71-75 over "the HYACJ27 cDNA" because this recitation lacks antecedent basis.

5. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

6. Claims 11-12, 14 and 36-75 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claims 11-12, 14 and 36-75 are directed to isolated proteins at least 90% identical to SEQ ID NO: 56 and contiguous amino acid residues of SEQ ID NO: 56. Claims reciting 90%

Art Unit: 1637

sequence identity are inclusive of sequences from other species, mutated sequences, and allelic variants having different functional activities than that of the protein in SEQ ID NO: 56. Claims drawn to proteins comprising any 30 or 50 contiguous amino acid residues of SEQ ID NO: 56, includes a large genus of proteins, having unique functional activities, whereas applicants only disclose one member of the genus (i.e. SEQ ID NO: 56) and haven't disclosed any other proteins having portions of SEQ ID NO: 56. In addition, proteins having any 30 or 50 residues of SEQ ID NO: 56 would be expected to have unique functional activities, wherein the specification has not disclosed any proteins having functional activities different from those of SEQ ID NO: 56. None of these sequences meet the written description provision of 35 USC 112, first paragraph. The specification provides insufficient written description to support the genus encompassed by the claims.

Vas-Cath Inc. v. Mahurkar, 19 USPQ2d 1111, makes clear that "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession *of the invention*. The invention is, for purposes of the 'written description' inquiry, *whatever is now claimed*." (See page 1117.) The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See Vas-Cath at page 1116.)

The skilled artisan cannot envision the detailed chemical structure of the encompassed proteins, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it. The nucleic acid itself is required. See Fiers v. Revel, 25 USPQ2d 1601, 1606 (CAFC 1993), and Amgen Inc. V. Chugai Pharmaceutical Co. Ltd., 18

Art Unit: 1637

USPQ2d 1016. In Fiddes v. Baird, 30 USPQ2d 1481, 1483, claims directed to mammalian FGF's were found unpatentable due to lack of written description for the broad class. The specification provided only the bovine sequence.

Finally, University of California v. Eli Lilly and Co., 43 USPQ2d 1398, 1404, 1405 held that:

To fulfill the written description requirement, a patent specification must describe an invention and do so in sufficient detail that one skilled in the art can clearly conclude that "the inventor invented the claimed invention." *Lockwood v. American Airlines, Inc.*, 107 F.3d 1565, 1572, 41 USPQ2d 1961, 1966 (1997); *In re Gosteli*, 872 F.2d 1008, 1012, 10 USPQ2d 1614, 1618 (Fed. Cir. 1989) (" [T]he description must clearly allow persons of ordinary skill in the art to recognize that [the inventor] invented what is claimed."). Thus, an applicant complies with the written description requirement "by describing the invention, with all its claimed limitations, not that which makes it obvious," and by using "such descriptive means as words, structures, figures, diagrams, formulas, etc., that set forth the claimed invention." *Lockwood*, 107 F.3d at 1572, 41 USPQ2d at 1966.

An adequate written description of a DNA, such as the cDNA of the recombinant plasmids and microorganisms of the '525 patent, "requires a precise definition, such as by structure, formula, chemical name, or physical properties," not a mere wish or plan for obtaining the claimed chemical invention. *Fiers v. Revel*, 984 F.2d 1164, 1171, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993). Accordingly, "an adequate written description of a DNA requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it; what is required is a description of the DNA itself." *Id.* at 1170, 25 USPQ2d at 1606.

### ***Claim Rejections - 35 USC 101***

7. 35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

8. Claims 11-12, 14 and 24-75 are rejected under 35 U.S.C. 101 because the claimed invention lacks patentable utility, due to its not being supported by either specific or substantial asserted utility or a well-established utility.

The specification fails to provide objective evidence of any activity for the encoded protein. The specification (page 36) states that the gene (i.e. HYACJ27cDNA) encoding SEQ ID NO: 56 is expressed "primarily" in B-cell lymphoma.

The specification postulates that expression of the protein of SEQ ID NO: 56 may be useful in treatment and diagnoses of cancers and disorders of the immune and hemopoietic systems, including but not limited to anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia. The specification at page 36, further suggests that the protein of SEQ ID NO: 56 could be used in the treatment of immunological disorders, such as infection, inflammation, allergy, immunodeficiency, etc.

In order for a polypeptide to be useful for diagnosis of a disease, there must be a well-established or disclosed correlation or relationship between the claimed polypeptide and a disease or disorder. The presence of a polypeptide in tissue that is derived from cancer cells is not sufficient for establishing a utility in diagnosis of disease in the absence of some information regarding a correlative or causal relationship between the expression of the claimed cDNA and the disease. If a molecule is to be used as a surrogate for a disease state, some disease state must be identified in some way with the molecule. There must be some expression pattern that would allow the claimed polypeptide to be used in a diagnostic manner. Many proteins are expressed in normal tissues and diseased tissues. Therefore, one needs to know, e.g., that the claimed polypeptide is either present only in cancer tissue to the exclusion of normal tissue or is expressed in higher levels in diseased tissue compared to normal tissue (i.e. overexpression). Evidence of a differential expression might serve as a basis for use of the claimed polypeptide as a diagnostic for a disease. However, in the absence of any disclosed relationship between the claimed protein or the polynucleotide encoded said protein and any disease or disorder and the lack of any correlation between the claimed polynucleotide or the encoded protein with any known disease or disorder, any information obtained from an expression profile would only

serve as the basis for further research on the observation itself. "Congress intended that no patent be granted on a chemical compound whose sole 'utility' consists of its potential role as an object of use-testing." *Brenner*, 148 USPQ at 696. The disclosure does not present a substantial or well established utility that would support the requirement of 35 U.S.C. §101.

The specification asserts that the claimed protein is useful in assaying proteins in a biological sample (pg. 178), molecular weight markers on DS-PAGE gels or on molecular sieve gel filtration columns (179), and for raising antibodies (pg. 179). These utilities, however, would apply to virtually every member of a general class of materials, such as any collection of proteins. Therefore, they are not considered to be specific and substantial utilities with regard to the instantly claimed nucleic acids.

Accordingly, the claimed invention is not supported by either a specific or substantial asserted utility or a well-established utility.

Applicant should explicitly identify a specific, substantial, and credible utility for the claimed invention and establish a probative relation between any evidence of record and the originally disclosed properties of the claimed invention.

9. Claims 11-12, 14 and 24-75 are also rejected under 35 U.S.C. §112, first paragraph.

Specifically, since the claimed invention is not supported by a specific, substantial, and credible utility or a well-established utility for the reasons set forth above, one skilled in the art would not know how to use the claimed invention.

### *Conclusion*

10. No claims are allowable.




Art Unit: 1637


*Correspondence*

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alexander H. Spiegler whose telephone number is (703) 305-0806. The examiner can normally be reached on Monday through Friday, 7:00 AM to 3:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on (703) 308-1119. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 and (703) 305-3014. Applicant is also invited to contact the TC 1600 Customer Service Hotline at (703) 308-0198.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

  
Alexander H. Spiegler  
May 30, 2002

  
KENNETH R. HORLICK, PH.D  
PRIMARY EXAMINER

5/30/02